Ask most clinical trial teams how a mask gets broken, and they will describe a randomization code getting exposed. That is one way it happens. It is not the only way, and for one global, randomized, double-mask ophthalmology trial we supported, it was not even the most likely way.
The study ran for 18 months per subject, with more than 20 protocol-defined visits, temperature-controlled investigational product, and sites in multiple countries that needed continuous, uninterrupted drug supply. None of that sounds like a masking problem at first, but there are challenges that sponsors must address.
If a site only ever receives a single kit of one drug type, and that pattern holds over time, an observant site or depot can start to infer treatment assignment without ever seeing a randomization code. Shipment size, shipment contents, and resupply timing can all leak information, especially in a study long enough and complex enough for patterns to emerge.
The Task: Keep Patients’ Details Private During The Study
The ophthalmology trial required significantly more than subject randomization. The design included an 18-month treatment period, 20-plus protocol-defined visits, temperature-controlled investigational product, emergency unmasking requirements, kit replacement workflows, and predictive supply management across multiple countries and sites.
Treatment assignments could not be inferred from inventory levels, shipment contents, resupply behavior, or site-specific drug availability. At the same time, sites needed continuous access to study drug despite the long treatment duration, tight visit windows, and the potential for temperature excursions, damaged shipments, or replacement dosing events.
The sponsor needed an IRT platform capable of managing the entire subject and supply lifecycle while preserving masking, maintaining compliance, and providing complete traceability from batch release through assignment.
The Solution: Building Supply Logic Focused on the Mask, Beyond Just Randomization
YPrime designed and validated our IRT platform to combine participant randomization, visit management, inventory control, predictive resupply, temperature excursion workflows, and emergency unmasking within a single system.
The resupply logic intentionally ordered multiple kits together rather than one at a time, helping reduce the risk that shipment size and contents could reveal a subject’s treatment assignment or treatment grouping. The platform also applied a tiered temperature excursion model: a range where product remained automatically approved for use, a wider range where product could remain in use only up to a defined duration before quarantine, and any reading outside the allowed range, which triggered automatic quarantine regardless of duration. That tiered logic prevented unnecessary quarantine from brief, low-risk deviations while still protecting patients from prolonged or extreme excursions.
What the Solution Provided:
- A validated, masked IRT platform integrating randomization, dispensing, and supply management
- Advanced masked resupply logic designed to prevent treatment inference through shipment or inventory patterns
- A tiered temperature excursion model distinguishing automatic approval, duration-based quarantine, and immediate quarantine for out-of-range readings
- Controlled emergency unmasking with full audit traceability from batch release through assignment
The Findings
The mask held for the entire 18-month treatment period, across a complex global supply network, with no interruption to drug supply at any site.
- Maintained treatment masking across a complex global supply network throughout an extended, multi-visit treatment period
- Uninterrupted drug supply through predictive inventory management and automated resupply
- Audit-ready traceability and reporting from depot through dispensation, supporting inspection readiness
Why Clinical Trial Masking Should Cover the Supply Chain
For sponsors running long-duration, globally distributed, or operationally complex trials, masking protection cannot stop at the randomization system. Supply chain design, temperature management, and emergency unmasking controls all need to work together to prevent inference and protect study integrity.
New to IRT? Read: What Is IRT in Clinical Trials and Why Does It Matter?
Frequently Asked Questions
Masking protection means ensuring that treatment assignment cannot be determined by investigators, site staff, or sponsors through any channel, not just the randomization system itself. This includes preventing inference through shipment contents, resupply timing, inventory levels, or site-specific drug availability.
Yes. If a site consistently receives supply patterns tied to a specific drug type, such as single-kit shipments or predictable resupply timing, those patterns can allow treatment assignment to be inferred without ever accessing the randomization code. This is why masked supply management logic, not just randomization logic, is essential in complex studies.
A temperature excursion occurs when investigational product is exposed to temperatures outside its approved storage range. Well-designed IRT platforms manage this with tiered logic: product within an approved range remains usable, product in a wider allowed range may be used only up to a defined duration before quarantine, and product outside the allowed range is quarantined automatically regardless of duration.
Emergency unmasking is the controlled process of revealing a subject’s treatment assignment outside the normal course of a trial, typically for safety reasons. IRT platforms support this by restricting unmasking access to authorized personnel, logging every request and outcome, and preserving study continuity and audit traceability throughout the process.
Ophthalmology trials can involve long treatment durations, frequent scheduled visits, and temperature-controlled investigational product, all of which create more opportunities for supply chain patterns to develop over time. A platform built to manage that complexity while protecting the mask is essential to preserving the validity of the trial’s integrity.
Check Out What Our Experts Have to Say
about trial design, data capture, operational efficiencies, and, ultimately, how to solve with certainty in clinical research.
